<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05069298</url>
  </required_header>
  <id_info>
    <org_study_id>BIO-HPC_1</org_study_id>
    <nct_id>NCT05069298</nct_id>
  </id_info>
  <brief_title>Effect of Silibinin(A) as a Potential Anti-obesity Agent</brief_title>
  <official_title>Effect of Milk Thistle Derivative Silibinin(A) as a Potential Anti-obesity Agent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Católica San Antonio de Murcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Católica San Antonio de Murcia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our preliminary reports have found in silico and in vitro that the milk thistle derivative&#xD;
      Silibinin(A) is able to inhibit pancreatic lipase, in a similar way that the classical&#xD;
      anti-obesity drug orlistat.&#xD;
&#xD;
      Therefore, the investigators want to carry out the present trial in order to confirm that&#xD;
      Silibinin(A) is able to in vivo inhibit pancreatic lipase, which will reduce the fat&#xD;
      absorption and therefore will decrease the amount of energy from food intake.&#xD;
&#xD;
      Considering that milk thistle has been extensively studied in humans as liver-protector, the&#xD;
      investigators consider that the use of human subjects will be of great interest to accelerate&#xD;
      the employment of this compound to improve the effectiveness of dietary treatment in&#xD;
      overweight/obese subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">December 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of total body weight loss</measure>
    <time_frame>3 months</time_frame>
    <description>Change in body weight from baseline to the end of study period (3 months).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma total cholesterol</measure>
    <time_frame>3 months</time_frame>
    <description>Change in plasma total cholesterol levels from baseline to the end of study period (3 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma low density level cholesterol (cLDL)</measure>
    <time_frame>3 months</time_frame>
    <description>Change in plasma cLDL levels from baseline to the end of study period (3 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma triglycerides</measure>
    <time_frame>3 months</time_frame>
    <description>Change in plasma triglyceride levels from baseline to the end of study period (3 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index (BMI)</measure>
    <time_frame>3 months</time_frame>
    <description>Change in BMI from baseline to the end of study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat percentage</measure>
    <time_frame>3 months</time_frame>
    <description>Change in body fat from baseline to the end of study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>3 months</time_frame>
    <description>Change in waist circumference from baseline to the end of study period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Overweight and Obesity</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>INTERVENTION</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Silibinin (A) for three months, with an administration regimen of 3 oral doses of 300 mg per day, before each main meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Similar treatment regimen, but with a placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Silibinin A</intervention_name>
    <description>The compound will be administered following a 300 mg / 3 day schedule, before each main meal.</description>
    <arm_group_label>CONTROL</arm_group_label>
    <arm_group_label>INTERVENTION</arm_group_label>
    <other_name>Milk thistle derivative</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI &gt; 24,9&#xD;
&#xD;
          -  Voluntarily participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  significant cognitive impairment&#xD;
&#xD;
          -  psychiatric disorders&#xD;
&#xD;
          -  chronic pharmacological treatment that may affect the effectiveness of the dietary&#xD;
             intervention (corticosteroids, thyroid hormones, oral antidiabetic agents or&#xD;
             lipid-lowering drugs)&#xD;
&#xD;
          -  chronic disease that may interfere with dietary therapy (cancer, renal or hepatic&#xD;
             impairment, chronic gastrointestinal conditions)&#xD;
&#xD;
          -  acute disease episodes during the study&#xD;
&#xD;
          -  subjects who followed a hypocaloric diet at the allocation time or in the 3 months&#xD;
             prior to the beginning of the study&#xD;
&#xD;
          -  pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan José Hernández Morante, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University of Murcia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan José Hernández Morante, PhD</last_name>
    <phone>34968278808</phone>
    <email>jjhernandez@ucam.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Nursing. Catholic University of Murcia</name>
      <address>
        <city>Murcia</city>
        <zip>30107</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://bio-hpc.ucam.edu/ucamhealth/</url>
    <description>Webpage of the research group and contact info.</description>
  </link>
  <link>
    <url>http://bio-hpc.ucam.edu/</url>
    <description>Webpage of other collaborators</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 29, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Católica San Antonio de Murcia</investigator_affiliation>
    <investigator_full_name>Juan Jose Hernández Morante</investigator_full_name>
    <investigator_title>Main researcher at Eating-related disorders research unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silybin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The data derived from the present trial will be located in public domain databases, concretely in the Mendeley data repository (https://data.mendeley.com/). Nevertheless, all data will be available by request to the main researcher, Dr. Juan José Hernández Morante (e-mail:jjhernandez@ucam.edu).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

